IL1R1 and infection: Of note, therapeutic targeting of IL‐1R via intravenous treatment with recombinant IL‐1R antagonist from day 2 following infection was shown to improve survival35; however, inflammation in the lung was unfortunately not examined by the authors, nor the possibility that as per studies in IL‐1R–/– mice, inhibition of IL‐1R from day 1 could result in increased susceptibility to infection.